NEW YORK, NY / ACCESSWIRE / June 5, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links provided.
Boston Scientific Corporation (BSX)
Class Period: February 26, 2015 - April 16, 2019
Lead Plaintiff Deadline : June 24, 2019
Join the action: https://www.zlk.com/pslra-1/boston-scientific-corporation-loss-form?prid=1823&wire=1
Allegations: Boston Scientific Corporation made materially false and/or misleading statements throughout the class period and/or failed to disclose that: (i) Boston Scientific's surgical mesh products indicated for the transvaginal repair of pelvic organ prolapse ("POP") were unsafe; (ii) accordingly, Boston Scientific's continued marketing and sales of these devices in the United States was unlikely to be sustainable; (iii) separately, the Company had sold vaginal mesh implants containing counterfeit or adulterated resin products imported from China; (iv) the foregoing conduct subjected the Company to a heightened risk of regulatory scrutiny and/or government investigations; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.
To learn more about the Boston Scientific Corporation class action contact email@example.com.
Intersect ENT, Inc. (XENT)
Class Period: August 1, 2018 - May 6, 2019
Lead Plaintiff Deadline : July 15, 2019
Join the action: https://www.zlk.com/pslra-1/intersect-ent-inc-loss-form?prid=1823&wire=1
Allegations: Intersect ENT, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) Intersect lacked adequate reimbursement representatives to ensure physicians had access to SINUVA, Intersect's sinus implant; (2) Intersect's sales force would focus on ensuring reimbursement; (3) Intersect's sales representatives were less focused on driving sales; (4) physicians were less likely to adopt Intersect's SINUVA due to transaction costs associated with seeking reimbursement; (5) Intersect would increase staffing to address these issues; and (6) as a result of the foregoing, defendants' positive statements about Intersect's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
To learn more about the Intersect ENT, Inc. class action contact firstname.lastname@example.org.
comScore, Inc. (SCOR)
Class Period: November 8, 2018 - March 29, 2019
Lead Plaintiff Deadline : June 10, 2019
Join the action: https://www.zlk.com/pslra-1/comscore-inc-loss-form?prid=1823&wire=1
Allegations: During the class period, comScore, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) that the Company was experiencing difficulties implementing its business strategy; (2) that, as a result, the Company's financial results would be materially impacted; and (3) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
To learn more about the comScore, Inc. class action contact email@example.com.
You have until the lead plaintiff deadlines to request the court appoint as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
SOURCE: Levi & Korsinsky, LLP
View source version on accesswire.com: